Vision correction surgery trial to study both eyes
This article was originally published in Clinica
Executive Summary
US vision correction company Refractec is to begin treating both eyes of patients on the same day with its conductive keratoplasty (CKT) technique as part of a modified clinical trial of hyperopia correction. The US FDA approved the change to the Phase III trial based on hyperopic stability data during a one to nine month follow-up, which were equal to or better than that of competitors in the field, according to the Irvine, California-based company.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.